- In May 2025, Thermo Fisher Scientific Inc. announced the launch of its next-generation RNA sequencing platform designed to enhance transcriptomic profiling capabilities in clinical research. The platform integrates automation and cloud-based analytics, enabling researchers to conduct high-throughput transcriptome analysis with greater efficiency and reproducibility. This innovation underscores Thermo Fisher’s commitment to advancing precision medicine through powerful omics technologies
- In April 2025, Illumina, Inc. collaborated with a leading academic consortium in Europe to develop AI-driven transcriptomics tools for cancer diagnostics. The partnership aims to harness machine learning algorithms to identify gene expression signatures associated with early-stage tumors, accelerating the development of personalized treatment protocols. This initiative is part of Illumina's broader push to integrate AI into its genomics ecosystem
- In March 2025, Qiagen launched a new range of multiplex PCR kits optimized for transcriptomic biomarker discovery in autoimmune and neurodegenerative diseases. The kits are designed for use in translational research and clinical trials, offering enhanced sensitivity and reproducibility for low-expressing genes. The development marks Qiagen’s strategic expansion into disease-specific transcriptomic solutions
- In February 2025, 10x Genomics unveiled its Spatial Molecular Imager (SMI) for advanced tissue transcriptomics, capable of mapping gene expression at subcellular resolution. The system, tailored for oncology and immunology research, provides spatial context to transcriptomic data, unlocking deeper insights into tissue microenvironments. This innovation is expected to significantly advance biomarker discovery and therapeutic development
- In January 2025, Takara Bio Inc. announced the commercial availability of its Smart-seq Single Cell Transcriptomics Kit, which simplifies high-throughput single-cell RNA sequencing workflows. The kit, compatible with leading sequencing platforms, targets researchers in immunology and stem cell biology. The launch supports Takara Bio’s vision of democratizing access to single-cell technologies in both academic and clinical research setting
